Acute promyelocytic leukemia M3: Cytomorphologic, immunophenotypic, cytogenetic, and molecular variants

Journal of Hematotherapy and Stem Cell Research

Volumn 11, Issue 6, 2002, Pages 941-950

  Sučić, Mirna ^a   Zadro, Renata ^a   Burazer, Branka ^a   Labar, Boris ^b   Nemet, Damir ^b   Mrsić, Mirando ^b   Aurer, Igor ^b   Mrsić, Sanja ^a   Hitrec, Vlasta ^b   Boban, Dubravka ^a   Marković Glamočak, Mirjana ^a   Batinić, Drago ^a   Užarević, Branka ^a   Stavljenić Rukavina, Ana ^a  

^a KBC Zagreb   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; GENE PRODUCT; HLA DR ANTIGEN; MICROSOMAL AMINOPEPTIDASE; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA M3; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CELL GRANULE; CELL HETEROGENEITY; CELL STRUCTURE; CHROMOSOME 15; CHROMOSOME 17; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION 15; CLINICAL ARTICLE; CYTOGENETICS; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKEMIA CELL; LEUKEMIA REMISSION; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; CELL SIZE; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROTEIN ISOFORMS; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 0036968552     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/152581602321080600     Document Type: Article

References (45)

1. Bennett JM, D Catovsky, MT Daniel, G Flandrin, DA Galton, HR Gralnick and C Sultan. (1976). Proposals for classification of acute leukemias. Br J Haematol 33:451-458.
2. Goasguen JE and JM Bennett. (1990). Classifications of acute myeloid leukemia. Clin Lab Med 10:661-681.
3. Behm FG. (1999). Diagnosis of childhood acute myeloid leukemia. Clin Lab Med 19:187-237.
4. Elghetany MT, JM MacCallum and FR Davey. (1990). The use of cytochemical procedures in the diagnosis and management of acute and chronic myeloid leukemia. Clin Lab Med 10:707-719.
5. Fenaux P, C Chomienne and L Degos. (1997). Acute promyelocytic leukemia: biology and treatment. Semin Oncol 24:92-102.
6. Bartolo C and DS Viswanatha. (2000). Molecular diagnosis in pediatric acute leukemias. Clin Lab Med 20:139-180.
7. Biondi A, A Rambaldi, PP Pandolfi, V Rossi, G Giudici, M Alcalay, F Lo Coco, D Diverio, EM Pogliani, EM Lanzi, F Mandelli, G Masera, T Barbui and G Pelicci. (1992). Molecular monitoring of the mylretinoic acid receptor-α fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 80:492-497.
8. Gogineni SK, HO Shah, M Chester, JH Lin, M Garrison, A Alidina, E Bayani and RS Verma. (1997). Variant complex translocations involving chromosomes 1, 9, 15 and 17 in acute promyelocytic leukemia without RARalpha/PML gene fusion rearrangement. Leukemia 11:514-518.
9. Wells RA, JL Hummel, A De Koven, A Zipursky, M Kirby, I Dube and S Kamel-Reid. (1996). A new variant translocation in acute promyelocytic leukemia: a molecular characterization and clinical correlation. Leukemia 10:735-740.
10. Arranz E, JL Lopez, M Robledo, B Martinez, A Escudero and J Benitez. (1996). Rearrangement of one RAR-α gene in an acute promyelocytic leukemia case with t(15;17) and t(6;17) involving chromosomes 17 and band q21. Cancer Genet Cytogenet 87:172-175.
11. Swirsky DM, M de Bastos, SE Parish, JK Rees and FG Hyhoe. (1986). Features affecting outcome during remission induction of acute myeloid leukaemia in 619 adult patients. Br J Haematol 64:435-453.
12. Mandelli F, D Diverio, G Avvisati, A Luciano, T Barbui, C Bernasconi, G Broccia, R Cerri, M Falda, G Fioritoni, F Leoni, V Liso, MC Petti, F Rodeghiero, G Saglio, ML Vegna, G Visani, U Jehn, R Willemze, P Muus, PG Pelicci, A Biondi and F Lo Coco. (1997). Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 90:1014-1021.
13. Cheson BD, PA Cassileth, DR Head, CA Schiffer, JM Bennett, CD Bloomfield, R Brunning, RP Gale, MR Grever, MJ Keating, A Sawitsky, S Stass, H Weinstein and WG Woods. (1990). Report of the NCI-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819.
14. Harris NL, ES Jaffe, J Diebold, G Flandrin, HK Muller-Hermelink, J Vardiman, TA Lister and CD Bloomfield. (2000). The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Hematol J 1:53-66.
15. Batinić D. (1989). Flow-cytometric immunophenotyping of acute leukemia. Bone Marrow Transplant 4 (suppl 3):13-15.
16. Terstappen LW, M Safford, S Konemann, MR Loken, K Zurlutter, T Buchner, W Hiddemann and B Wormann. (1992). Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis. Leukemia 6:70-80.
17. Boban D, M Sučić, M Marković-Glamocak, B Užarević, D Batinić, M Marušić, D Nemet, B Labar and V Hitrec. (1993). Correlation of morphological FAB classification and immunophenotyping: value in recognition of morphological, cytochemical and immunological characteristics of mixed leukemias. Eur J Cancer 29A:1167-1172.
18. Heim S and F Mitelman. (1992). Cytogenetic analysis in the diagnosis of acute leukemia. Cancer 70:1701-1709.
19. Hintze IL. (1987). "Number cruncher statistical system (version 5.01)." Kayssville, UT.
20. Campana D and CH Pui. (1995). Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 85:1416-1434.
21. Buchner T and A Heinecke. (1996). The role of prognostic factors in acute myeloid leukemia. Leukemia, 10(Suppl 1):S28-S29.
22. Dastugue N, C Payen, M Lafage-Pochitaloff, P Bernard, D Leroux, F Huguet-Rigal, AM Stoppa, G Marit, L Molina, M Michallet et al. (1995). Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia 9:1491-1498.
23. Ino T, M Tsuzuki, M Okamoto, M Shamoto and M Hirano. (1999). Acute leukemia with the phenotype of a natural killer/T cell bipotential precursor. Ann Hematol 78:43-47.
24. Khalidi HS, LJ Medeiros, KL Chang, RK Brynes, ML Slovak and DA Arber. (1998). The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities. Am J Clin Pathol 109:211-220.
25. Exner M, R Thalhammer, S Kapiotis, G Mitterbauer, P Knobl, OA Haas, U Jager and I Schwarzinger. (2000). The "typical" immunophenotype of acute promyelocytic leukemia (APL-M3): does it prove true for the M3-variant? Cytometry 42:396-397.
26. - myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3. Blood 84:224-255.
27. Del Poeta G, R Stasi, A Venditti, G Suppo, G Aronica, A Bruno, M Masi, A Tabilio and G Papa. (1994). Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia 8:388-394.
28. Paietta E, J Andersen, R Gallagher, J Bennett, J Yunis, P Cassileth, J Rowe and PH Wiemik. (1994). The immunophenotype of acute promyelocytic leukemia (APL): an ECOG study. Leukemia 8:1108-1112.
29. Fukuno K, H Tsurumi, T Yoshikawa, T Yamada, M Oyama and H Moriwaki. (2001). A variant form of acute promyelocytic leukemia with marked myelofibrosis. Int J Hematol 74:322-326.
30. Guglielmi C, MP Martelli, D Diverio, S Fenu, ML Vegna, A Cantu-Rajnoldi, A Biondi, MG Cocito, L Del Vecchio, A Tabilio, G Avvisati, G Basso and F Lo Coco. (1998). Immunophenotype of adult and childhood acute promyelocytic leukemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. Br J Haematol 102:1035-1041.
31. Fergedal M, M Astrom, U Tidefelt and MG Karlsson. (1998). Differences in CD14 and alpha-naphthyl acetate esterase positivity and relation to prognosis in AML. Leuk Res 22:25-30.
32. Dubosc-Marchenay N, F Lacombe, P Dumain, G Marit, M Montastruc, F Belloc and J Reiffers. (1992). Role of blast cell immunophenotyping for the diagnosis and prognosis of acute myeloid leukemia. Hematol Oncol 10:235-249.
33. Ball ED, RB Davis, JD Griffin, RJ Mayer, FR Davey, DC Arthur, D Wurster-Hill, W Noll, MT Elghetany, SL Allen, K Rai, EJ Lee, CA Schiffer and CD Bloomfield. (1988). Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood 77:2242-2250.
34. Miwa H, K Kita, K Nishii, N Morita, N Takakura, K Ohishi, N Mahmud, S Kageyama, M Fukumoto and S Shirakawa. (1993). Expression of MDR1 gene in acute leukemia cells: association with CD7 acute myeloblastic leukemia/acute lymphoblastic leukemia. Blood 82:3445-3451.
35. Wan TS, CS Chim, CK So, LC Chan and SK Ma. (1999). Complex variant 15;17 translocations in acute promyelocytic leukemia. A case report and review of three-way translocations. Cancer Genet Cytogenet 111:139-143.
36. Zhou DC, SH Kim, W Ding, C Schultz, RP Warrell Jr and RE Gallagher. (2002). Frequent mutations in the ligand-binding domain of PML-RARα after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood 99:1356-1363.
37. Kolomietz E, J Al-Maghrabi, S Brennan, J Karaskova, S Minkin, J Lipton and JA Squire. (2001). Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 97:3581-3588.
38. Gallagher RE, CL Willman, JL Slack, JW Andersen, YP Li, D Viswanatha, CD Bloomfield, FR Appelbaum, CA Schiffer, Tallman MS and PH Wiernik. (1997). Association of PML-RARα fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood 90:1656-1663.
39. Jurcic JG, SD Nimer, DA Scheinberg, T De Blasio, RP Warrell Jr and WH Miller Jr. (2001). Prognostic significance of minimal residual disease detection and PML/RAR-α isoform type: long-term follow-up in acute promyelocytic leukemia. Blood 98:2651-2656.
40. Huang W, GL Sun, XS Li, G Cao, Y Lu, GS Jang, FQ Zhang, ZY Wang, S Waxman et al. (1993). Acute promyelocytic leukemia: clinical relevance of two major PMLRAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood 82:1264-1269.
41. Slack JL and M Yu. (1998). Constitutive expression of promyelocytic leukemia-associated oncogene PML-RARα in TF1 cells: isoform-specific and retinoic acid-dependent effects on growth, bcl-2 expression, and apoptosis. Blood 91:3347-3356.
42. Jurcic JG, T DeBlasio, L Dumont, TJ Yao and DA Scheinberg. (2000). Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM 195 in acute promyelocytic leukemia. Clin Cancer Res 6:372-380.
43. Gameiro P, S Vieira, P Carrara, AL Silva, J Diamond, A Batelho de Sousa, AB Mehta, HG Prentice, JE Guimaraes, AV Hoffbrand, L Foroni and A Parreira. (2001). The PMLRAR alpha transcript in long-term follow-up of acute promyelocytic leukemia patients. Haematologica 86:577-585.
44. Miller WH Jr, K Levine, A DeBlasio, SR Frankel, E Dmitrovsky and RP Warrell Jr. (1993). Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA. Blood 82:1689-1694.
45. Viniou NA, X Yataganas, K Stamatopoulos, I Xefteri, T Kalmantis, P Papasavas, C Mitsulis, J Rombos, J Meletis, K Bourantas et al. (1995). Reverse transcription polymerase chain reaction for the diagnosis and molecular monitoring of the PML/RAR alpha fusion gene in acute promyelocytic leukemia. Cancer Genet Cytogenetic 84:91-94.